Enveric Biosciences, Inc. is a biotechnology company. Co. is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. Co., through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. We show 19 historical shares outstanding datapoints in our coverage of ENVB's shares outstanding history.
Understanding the changing numbers of ENVB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ENVB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ENVB by allowing them to research ENVB shares outstanding history
as well as any other stock in our coverage universe. |
Free ENVB Email Alerts:
Video: Shares Outstanding Importance
